Literature DB >> 20158602

The burden of hepatitis C in Sweden: a national study of inpatient care.

A-S Duberg1, H Pettersson, S Aleman, A Blaxhult, L Daviðsdóttir, R Hultcrantz, E Bäck, K Ekdahl, S M Montgomery.   

Abstract

The spread of hepatitis C virus (HCV) in Sweden in the 1970s indicated that serious liver complications (SLC) would increase in the 2000s. The aim of this study was to analyse the burden of HCV-associated inpatient care in Sweden, to demonstrate the changes over time and to compare the findings with a noninfected population. The HCV-cohort (n: 43,000) was identified from the national surveillance database 1990-2006, and then linked to national registers to produce an age-, sex-, and region-matched noninfected comparison population (n: 215,000) and to obtain information on demographics, cancers, inpatient care and prescriptions. Cox regression was used to estimate the likelihood (hazard ratios) for admission to hospital in the HCV compared with the noninfected cohort. The hazard ratios were 4.03 (95% CI: 3.98-4.08) for all care, 77.52 (71.02-84.60) for liver-related care and 40.74 (30.58-54.27) for liver cancer care. The admission rate in the HCV-cohort compared with the noninfected cohort, the rate ratio (age- and sex-adjusted) for all inpatient care was 5.91 (95% CI: 5.87-5.94), and the rate ratio for liver-related care was 70.05 (66.06-74.28). In the HCV-cohort, 45% of all episodes were for psychiatric, mostly drug-related, care. Inpatient care for SLC increased in the 2000s. To conclude, drug-related care was common in the HCV-infected cohort, the demand for liver-related care was very high, and SLC increased notably in the 2000s, indicating that the burden of inpatient care from serious liver disease in HCV-infected individuals in Sweden is an increasing problem.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 20158602     DOI: 10.1111/j.1365-2893.2010.01276.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

Review 1.  Protease inhibitors for hepatitis C: economic implications.

Authors:  Stuart J Turner; Jack Brown; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2013-09       Impact factor: 4.981

2.  Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden.

Authors:  Jonathan N Hofmann; Anna Törner; Wong-Ho Chow; Weimin Ye; Mark P Purdue; Ann-Sofi Duberg
Journal:  Eur J Cancer Prev       Date:  2011-07       Impact factor: 2.497

3.  Chronic pain treatment and health service utilization of veterans with hepatitis C virus infection.

Authors:  Travis I Lovejoy; Steven K Dobscha; Renee Cavanagh; Dennis C Turk; Benjamin J Morasco
Journal:  Pain Med       Date:  2012-09-07       Impact factor: 3.750

4.  Molecular characterization of HCV in a Swedish county over 8 years (2002-2009) reveals distinct transmission patterns.

Authors:  Josefine Ederth; Camilla Jern; Helené Norder; Lars Magnius; Erik Alm; Björg Kleverman Rognsvåg; Carl-Gustaf Sundin; Mia Brytting; Joakim Esbjörnsson; Mattias Mild
Journal:  Infect Ecol Epidemiol       Date:  2016-02-05

5.  Risk behaviour determinants among people who inject drugs in Stockholm, Sweden over a 10-year period, from 2002 to 2012.

Authors:  Niklas Karlsson; Michele Santacatterina; Kerstin Käll; Maria Hägerstrand; Susanne Wallin; Torsten Berglund; Anna Mia Ekström
Journal:  Harm Reduct J       Date:  2017-08-16

6.  Socioeconomic status in HCV infected patients - risk and prognosis.

Authors:  Lars Haukali Omland; Merete Osler; Peter Jepsen; Henrik Krarup; Nina Weis; Peer Brehm Christensen; Casper Roed; Henrik Toft Sørensen; Niels Obel
Journal:  Clin Epidemiol       Date:  2013-05-31       Impact factor: 4.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.